SunRISe-5 Trial: Evaluating TAR-200 for Recurrent High-Risk Non-Muscle Invasive Bladder Cancer - Sima Porten
Sima Porten
Sima Porten provides an overview of the SunRISe-5 trial, a Phase III study evaluating TAR-200, a novel drug delivery system for patients with recurrent high-risk non-muscle invasive bladder cancer (NMIBC) who have not responded to BCG treatment.
